Thompson Dean is the Co-CEO of Avista Capital Partners, a growth investment firm focused on healthcare. One of Avista's portfolio companies is Osmotica Pharmaceuticals, which analysts expect will see 74% year-over-year revenue growth as it brings new products to market after years of research and clinical trials. Osmotica is expected to become profitable starting in 2022 after operating nearly at breakeven, as the pharmaceutical industry typically experiences irregular cash flows depending on products' development stages.

1. Avista Portfolio
Company
Osmotica
Pharmaceuticals
Projects Growth
Thompson Dean

2. Introduction
Serving as Co-CEO of Avista Capital Partners, Thompson Dean focuses on growth
investments in health care sectors. Osmotica Pharmaceuticals, PLC is one of the portfolio
companies of Avista Capital Partners.
A recent article in Yahoo! Finance brought attention to Osmotica’s standing as a company
that, according to a trio of pharmaceuticals analysts, is operating nearly at breakeven.
Expectations are of an average 74 percent year-on-year expansion, which signals high
investor confidence. Anticipating its last loss in 2021, the company is expected to achieve
more than $40 million in profits in 2022.
This arc is described as being normal in the pharmaceuticals industry, which typically
experiences "irregular periods of cash flow,” depending on which stage of development
products are in. High growth rates are a result of new products that have gone through
years of research and clinical trials, then gaining FDA approval and going on the market.
Toward that end, Osmotica announced in May 2019 a positive topline result for its RVL
Phase III safety and efficacy clinical trial, which brings a groundbreaking ptosis treatment
one step closer to market launch.